drug
(dolutegravir sodium + rilpivirine hydrochloride)
Marketedupdated 3mo agoby ViiV Healthcare Company
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4all catalysts(0)
nothing on the calendar yet
Trials studying (dolutegravir sodium + rilpivirine hydrochloride)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 5, 2027
~1.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Sep 5, 2038formulationUS 12011506
- Jan 24, 2031compositionUS 104267804.5y
- Jun 8, 2030patentUS 9242986*PED3.9y
- Dec 8, 2029compositionUS 92429863.4y
- Apr 5, 2028patentUS 8129385*PED1.7y
- Oct 5, 2027compositionUS 81293851.2y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that